Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
MUSCULOSKELETAL SURGERY
Published in: MUSCULOSKELETAL SURGERY 3/2013

Open Access 01-12-2013 | Review

Practical management of new oral anticoagulants after total hip or total knee arthroplasty

Authors: W. Klauser, M. Dütsch

Published in: MUSCULOSKELETAL SURGERY | Issue 3/2013

Login to get access

Abstract

Within the past 5 years, the oral anticoagulants rivaroxaban, apixaban, and dabigatran etexilate have been approved for the prevention of venous thromboembolism in adult patients after elective hip or knee arthroplasty in the European Union and many other countries worldwide. These agents differ from the previously available anticoagulants because they selectively and directly inhibit a single factor in the coagulation cascade—rivaroxaban and apixaban inhibit Factor Xa, and dabigatran inhibits Factor IIa (thrombin)—potentially enhancing the predictability of their anticoagulant effect. Currently, although some guidelines provide recommendations for the use of rivaroxaban, dabigatran etexilate, and apixaban in clinical practice, there are still questions regarding the optimal practical management of patients receiving these agents. This article briefly reviews the practical limitations associated with conventional anticoagulants, discusses potential issues with the practical management of the newer oral anticoagulants, and provides clinical experience from a single institution where rivaroxaban and dabigatran etexilate have been used within their approved indications.
Literature
1.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88S
2.
Allen DJ, Chae-Kim SH, Trousdale DM (2002) Risks and complications of neuraxial anesthesia and the use of anticoagulation in the surgical patient. Proc (Bayl Univ Med Cent) 15:369–373
3.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2010) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:160S–198SCrossRef
4.
5.
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM et al (2004) Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181:492–497PubMed
6.
Barrett YC, Wang Z, Frost C, Shenker A (2010) Clinical laboratory measurement of direct Factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263–1271PubMedCrossRef
7.
8.
Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187PubMedCrossRef
9.
Bellamy L, Rosencher N, Eriksson B (2009) Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence 3:173–177PubMed
10.
11.
Boersma C, Kappelhoff BS, Postma MJ (2009) Administration advantages and cost-savings with dabigatran etexilate versus parenteral agents for thromboprophylaxis after major orthopaedic surgery in the Netherlands. Blood 114:563
12.
13.
Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9PubMedCrossRef
14.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
15.
Eriksson B, Turpie AGG, Lassen MR, Kakkar AK, Misselwitz F, Bandel TJ et al (2008) A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effects of specified co-medications. Blood (ASH Annual Meeting Abstracts) 112. Abstract 1986
16.
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef
17.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185PubMedCrossRef
18.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRef
19.
Eriksson BI, Kurth AA, Friedman RJ, Schnee JM, Clemens A, Noack H et al (2009) Risk of bleeding with dabigatran etexilate in patients undergoing major orthopaedic surgery is not increased by concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. J Thromb Haemost 7:374. Abstract PP-MO-167
20.
Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e278S–e325SPubMedCrossRef
21.
Favaloro EJ, Lippi G (2012) The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 22:329–341CrossRef
22.
Fischer HB, Simanski CJ (2005) A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement. Anaesthesia 60:1189–1202PubMedCrossRef
23.
Fischer HB, Simanski CJ, Sharp C, Bonnet F, Camu F, Neugebauer EA et al (2008) A procedure-specific systematic review and consensus recommendations for postoperative analgesia following total knee arthroplasty. Anaesthesia 63:1105–1123PubMedCrossRef
24.
Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr, Global Orthopaedic Registry Investigators (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMed
25.
Frost C, Lee L, Li LY, Nepal S, Shenker A, Reeves RA (2007) Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 47. Abstract 60
26.
Frost C, Yu Z, Moore K, Nepal S, Barrett R, Mosqueda-Garcia R et al (2007) Apixaban, an oral direct Factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2). Abstract P-M-664
27.
28.
Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e24S–e43SPubMedCrossRef
29.
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:381S–453SPubMedCrossRef
30.
Glassock RJ, Winearls C (2009) Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 120:419–428PubMed
31.
32.
Herkowitz HN, Dirschl DR, Sohn DH (2007) Pain management: the orthopaedic surgeon’s perspective. J Bone Joint Surg Am 89:2532–2535PubMedCrossRef
33.
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:141S–159SPubMedCrossRef
34.
Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med 28:172–197PubMed
35.
Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef
36.
Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct Factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol 46:981–990PubMedCrossRef
37.
Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Co-administration of rivaroxaban—a novel, oral, direct Factor Xa inhibitor—and clopidogrel in healthy subjects. Eur Heart J 28(Suppl 1):189. Abstract P1272
38.
Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757–2765PubMedCrossRef
39.
Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRef
40.
Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRef
41.
Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558PubMedCrossRef
42.
Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef
43.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604PubMedCrossRef
44.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487–2498
45.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, ADVANCE-2 Investigators (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815
46.
Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217–224PubMedCrossRef
47.
48.
49.
50.
Quante M, Thate-Waschke IM (2009) Comparative research between oral and subcutaneous thromboprophylaxis: the stopwatch project. Value Health 12:A339CrossRef
51.
Raskob GE, Hirsh J (2003) Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 124:379S–385SPubMedCrossRef
52.
Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900–5908PubMedCrossRef
53.
Rosencher N, Bonnet MP, Sessler DI (2007) Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 62:1154–1160PubMedCrossRef
54.
Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C et al (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:150–158PubMedCrossRef
55.
Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y et al (2012) Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387PubMedCrossRef
56.
Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau G, Depasse F et al (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct Factor Xa inhibitor. Thromb Haemost 103:815–825PubMedCrossRef
57.
58.
59.
60.
Smith SA, Morrissey JH (2007) Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors. Blood (ASH Annual Meeting Abstracts) 110. Abstract 928
61.
Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45:555–563PubMedCrossRef
62.
Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:138–143PubMedCrossRef
63.
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303PubMedCrossRef
64.
Stangier J, Stähle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59PubMedCrossRef
65.
The RE-MOBILIZE Writing Committee (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplast 24:1–9
66.
Turpie AGG, Gallus AS, Hoek JA, Pentasaccharide Investigators (2001) A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344:619–625PubMedCrossRef
67.
Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef
68.
Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE et al (2010) In vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38:448–458PubMedCrossRef
69.
Wong PC, Pinto DJ, Zhang D (2011) Preclinical discovery of apixaban, a direct and orally bioavailable Factor Xa inhibitor. J Thromb Thrombolysis 31:478–492PubMedCrossRef
Metadata
Title
Practical management of new oral anticoagulants after total hip or total knee arthroplasty
Authors
W. Klauser
M. Dütsch
Publication date
01-12-2013
Publisher
Springer Milan
Published in
MUSCULOSKELETAL SURGERY / Issue 3/2013
Print ISSN: 2035-5106
Electronic ISSN: 2035-5114
DOI
https://doi.org/10.1007/s12306-013-0306-8

Other articles of this Issue 3/2013

MUSCULOSKELETAL SURGERY 3/2013 Go to the issue

Case Report

Large soft tissue osteochondroma of the heel: a case report and literature review

Case Report

Heterotopic ossification of the elbow after closed reduction and retrograde intramedullary nailing for radial neck fracture treated by anconeus interposition

Case Report

Isolated rupture of biceps femoris tendon

Original Article

Surgical treatment for pelvic ring fractures in pediatric and adolescence age

Case Report

Primary intraosseous cavernous hemangioma of the toe

Original Article

Dirt bikes injuries in children